Valuation: Moderna, Inc.

Market Cap 22.75B 19.7B 18.36B 16.9B 31.88B 2,164B 32.25B 216B 84.6B 1,082B 85.45B 83.57B 3,588B P/E 2026 *
-6.64x
P/E 2027 * -11.6x
Enterprise Value 19.11B 16.54B 15.42B 14.19B 26.77B 1,817B 27.08B 181B 71.04B 909B 71.75B 70.17B 3,013B EV / Sales 2026 *
9.07x
EV / Sales 2027 * 8.46x
Free-Float
92.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.32%
1 week+0.81%
Current month+2.62%
1 month-29.47%
3 months+18.93%
6 months+31.53%
Current year+90.76%
1 week 52.66
Extreme 52.6601
59.49
1 month 52.66
Extreme 52.6601
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%+0.81%+103.53%-48.00% 22.75B
+1.04%+10.56%+34.48%+0.28% 75.96B
+2.64%-8.39%+24.13%+188.08% 49.03B
+1.02%-3.74%-7.47%+21.83% 47.88B
+1.42%+9.32%-50.68%-50.72% 43.39B
-0.87%+0.50%+56.30%-23.16% 30.8B
-0.66%-7.80%+53.51%+88.28% 24.45B
+4.15%+0.44%-2.80%+175.30% 19.24B
-0.10%-4.16%+71.71%+162.37% 16.04B
+1.05%-5.57%+63.38%+118.00% 15.87B
Average +1.10%-1.38%+34.61%+63.23% 34.54B
Weighted average by Cap. +1.16%+0.26%+25.32%+47.17%

Financials

2026 *2027 *
Net sales 2.11B 1.82B 1.7B 1.56B 2.95B 200B 2.98B 19.96B 7.83B 100B 7.91B 7.73B 332B 2.42B 2.1B 1.96B 1.8B 3.39B 230B 3.43B 22.97B 9.01B 115B 9.1B 8.9B 382B
Net income -3.38B -2.93B -2.73B -2.51B -4.73B -321B -4.79B -32.04B -12.56B -161B -12.69B -12.41B -533B -1.93B -1.67B -1.56B -1.43B -2.7B -183B -2.73B -18.28B -7.17B -91.68B -7.24B -7.08B -304B
Net Debt -3.65B -3.16B -2.94B -2.71B -5.11B -347B -5.17B -34.58B -13.56B -173B -13.7B -13.39B -575B -2.24B -1.94B -1.81B -1.67B -3.15B -213B -3.18B -21.28B -8.35B -107B -8.43B -8.24B -354B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
05/08/26 US$56.26 -1.29% 5,137,406
04/08/26 US$56.99 +3.36% 4,000,143
03/08/26 US$55.14 +0.58% 5,176,711
31/07/26 US$54.82 -5.35% 7,764,502
30/07/26 US$57.92 +6.29% 4,458,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
56.99USD
Average target price
50.84USD
Spread / Average Target
-10.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock